Global Panel Urges Rapid Reform of WHO and FCTC to Embrace Science, Transparency, and Consumer Voices
WASHINGTON, June 17, 2025 /CNW/ -- The Taxpayers Protection Alliance (TPA) is leading a robust and candid panel discussion on Wednesday alongside the Global Forum on Nicotine in Warsaw, Poland.
Consumer advocates will issue a resounding call for urgent reform of the taxpayer-funded World Health Organization (WHO) and its tobacco control arm, the Framework Convention on Tobacco Control (FCTC). The panel argues that years of politicized policymaking, opaque governance, and disregard for consumer perspectives have rendered the FCTC increasingly ineffective and out of touch with scientific and social realities.
Calls for reform of international health institutions have intensified in recent years, with the WHO's pandemic response drawing widespread criticism and renewed scrutiny of its broader governance failures. The FCTC has not been immune. With smoking rates not declining in many regions and growing disillusionment about the Convention's approach, panellists say it's time for a serious reset.
Martin Cullip, TPA International Fellow, observes that it has been clear for some time that WHO policies are missing the mark. "The FCTC has become a political instrument rather than a science-based treaty. If the WHO is serious about reform, the FCTC must be radically overhauled."
Ignacio Leiva, President of ASOVAPE in Chile, shares his country's perspective. "In Chile, including consumer voices helped us pass a law that recognizes the difference between smoking and vaping. That's exactly what the FCTC needs. Evidence-based policymaking built on dialogue, not dogma."
Nancy Loucas, representing Asian consumers, highlights the real-world harms of the WHO's current stance. "The WHO's policy shift against tobacco harm reduction ignores decades of evidence and disproportionately punishes low and middle-income countries. This isn't public health, it's health inequality."
Consumer advocacy is a recurring theme, with speakers emphasising the importance of hearing from the people most affected by nicotine policies.
Maria Papaioannoy of Rights 4 Vapers, Canada, emphasizes that "it's critical to counter the misinformation about safer nicotine products, especially when it comes from those in power. Consumers have voices, and it's time they were heard at FCTC COP11."
Tom Gleeson, Trustee of New Nicotine Alliance Ireland, echoes the call for evidence-based reform. "The FCTC hasn't adapted since 2005 to account for safer nicotine products," he said. "Instead, it pats itself on the back for reducing percentages while the number of smokers stays the same. The war on tobacco shouldn't come at the cost of the very people it's meant to help."
The panel discussion concludes with a unified appeal. Reform must focus on transparency, scientific integrity, and consumer inclusion. Participants call on the WHO and FCTC to step away from ideological posturing and prohibitionist strategies and instead commit to pragmatic policies that save lives.
The panel's message is clear. Real reform starts when science speaks louder than politics and when the people most affected are invited to the table.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
5 hours ago
- Cision Canada
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan."This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Vancouver Sun
9 hours ago
- Vancouver Sun
'Swallowing razor blades': What to know about the painful symptom linked to latest COVID strain
A painful symptom that has been linked to the latest strain of COVID-19 is being called 'razor blade throat.' The World Health Organization recently designated NB.1.8.1 as a variant under monitoring . The strain, nicknamed 'Nimbus,' has reportedly been causing extremely painful sort throats in those who have been infected with it. Cases of the Nimbus variant have been rising. It has been detected in 22 countries as of May 18 and made up 10.7 per cent of the global COVID samples taken in late April, WHO said. That was considered a 'significant rise in prevalence' since it only made up 2.5 per cent of global COVID samples four weeks prior. However, WHO deemed the overall risk of Nimbus to be low. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation,' according to WHO. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Here's what to know. Like the name suggests, 'razor blade throat' describes severe sore throat pain, as if the throat is 'covered with razor blades,' chair of the department of medicine and chief of infectious diseases at Mount Sinai South Nassau in New York Dr. Aaron Glatt told . 'While not specific to COVID-19,' he said, 'this expression has been used to describe sore throat symptoms in some patients with the most recent COVID-19 variant.' It has been described by some as 'akin to swallowing shattered glass or razor blades,' news network NTD reported . However, infectious disease specialist at University of California San Francisco Dr. Peter Chin-Hong, told the San Francisco Chronicle that a sore throat from COVID is 'not novel at all.' 'There has been a range of intensity of sore throat with COVID symptoms all along, including very severe pain,' said Chin-Hong. Other symptoms of COVID include runny nose, new or worsening cough, shortness of breath or difficulty breathing, fever, chills, fatigue or weakness, muscle or body aches, new loss of smell or taste, headache, abdominal pain, diarrhea and vomiting. This particular strain 'isn't too different from the Omicron variant , but it does have some tweaks to its spike protein,' according to general practitioner from private healthcare centre Pall Mall Medical in the United Kingdom Dr. Chun Tang, The Independent reported . That means it could 'spread a bit more easily or slip past some of our existing immunity.' 'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it,' said Tang. The earliest sample of Nimbus was taken in January, said WHO. In Canada, the federal government has been keeping track of COVID variants detected nationwide. Nimbus was detected in Canada in March, but it only accounted for a very low percentage of COVID strains in the country, at just 0.2 per cent . By the end of May, Nimbus made up roughly 20 per cent of all identified COVID cases. Using earlier trends to estimate the current situation, the government is predicting how variants will spread or diminish. This method is called nowcasting. For the week of June 1, the nowcasted estimates of Nimbus in Canada are predicted to be around 42 per cent. The nowcasted estimates for the week of June 15 jump to 53 per cent, meaning it would make up more than half of the cases in Canada if the prediction is accurate. Other than Canada, Nimbus has been detected around the world, with cases reported in India, Thailand, Hong Kong, Singapore and the United States, according to the World Health Network . It has also made its way to Australia and the United Kingdom .
Calgary Herald
9 hours ago
- Calgary Herald
'Swallowing razor blades': What to know about the painful symptom linked to latest COVID strain
Article content The World Health Organization recently designated NB.1.8.1 as a variant under monitoring. The strain, nicknamed 'Nimbus,' has reportedly been causing extremely painful sort throats in those who have been infected with it. Article content Cases of the Nimbus variant have been rising. It has been detected in 22 countries as of May 18 and made up 10.7 per cent of the global COVID samples taken in late April, WHO said. That was considered a 'significant rise in prevalence' since it only made up 2.5 per cent of global COVID samples four weeks prior. However, WHO deemed the overall risk of Nimbus to be low. Article content Article content 'While not specific to COVID-19,' he said, 'this expression has been used to describe sore throat symptoms in some patients with the most recent COVID-19 variant.' Article content It has been described by some as 'akin to swallowing shattered glass or razor blades,' news network NTD reported. Article content Article content However, infectious disease specialist at University of California San Francisco Dr. Peter Chin-Hong, told the San Francisco Chronicle that a sore throat from COVID is 'not novel at all.' Article content 'There has been a range of intensity of sore throat with COVID symptoms all along, including very severe pain,' said Chin-Hong. Article content Other symptoms of COVID include runny nose, new or worsening cough, shortness of breath or difficulty breathing, fever, chills, fatigue or weakness, muscle or body aches, new loss of smell or taste, headache, abdominal pain, diarrhea and vomiting. Article content Article content This particular strain 'isn't too different from the Omicron variant, but it does have some tweaks to its spike protein,' according to general practitioner from private healthcare centre Pall Mall Medical in the United Kingdom Dr. Chun Tang, The Independent reported. That means it could 'spread a bit more easily or slip past some of our existing immunity.'
